Singapore-headquartered Zuellig Pharma, a leading healthcare solutions provider, has entered into an agreement with US pharmaceutical giant Regeneron Pharmaceuticals Inc. to oversee the market launch and commercialization of Libtayo (cemiplimab), Regeneron’s proprietary programmed death-1 (PD-1) inhibitor, in South Korea and Taiwan. Financial details of the agreement were not disclosed.
Libtayo has received regulatory approval in South Korea for multiple indications, including first-line monotherapy for advanced non-small cell lung cancer (NSCLC), metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), and recurrent or metastatic cervical cancer. In Taiwan, it is approved as a monotherapy for advanced NSCLC. Zuellig Pharma, with its expertise in distribution and commercialization, particularly in the Asian and Australian markets, is well-positioned to support the successful introduction and expansion of Libtayo in these regions. – Flcube.com
